Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Study for the Treatment of Ulcerative Colitis With Adacolumn

Lead Sponsor:

Otsuka America Pharmaceutical

Conditions:

Ulcerative Colitis

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to demonstrate the safety and effectiveness of the Adacolumn Apheresis System to treat the signs and symptoms of ulcerative colitis.

Detailed Description

Trial Features: * Non-drug therapy * Most patients can remain on current treatment regimen, including prednisone, budesonide and medications such as Asacol (mesalamine), Pentasa (mesalamine), Colazal...

Eligibility Criteria

Inclusion

  • Key
  • Moderate to severe active ulcerative colitis with colonic involvement with ulcerative colitis beyond 15 cm of the anal verge
  • Adequate peripheral venous access to allow for completion of the apheresis treatments
  • Receiving one or more of the following medical therapies:
  • \*sulfasalazine, \*mesalamine and other 5-ASA agents, \*prednisone or 6-mercaptopurine or azathioprine OR Have not received the above medical therapies due to intolerance or demonstrated non-response
  • Agree to participate in the required follow-up visits
  • Able to complete a diary
  • Signed written informed consent document and authorization for use of protected health information
  • Key

Exclusion

  • Evidence of toxic megacolon
  • Major surgery within the past 6 weeks or anticipated need for surgery within 12 weeks
  • Proctocolectomy, total colectomy, ileostomy, stoma or ileal pouch-anal anastomosis
  • Requiring in-patient hospitalization
  • A history of allergic reaction to heparin or heparin-induced thrombocytopenia
  • A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures
  • A history of severe cardiovascular or peripheral arterial diseases
  • A history of cerebral vascular diseases
  • Liver diseases
  • Renal insufficiency
  • Insulin-dependent Type I or Type II diabetes
  • Known bleeding disorder or use of concomitant anticoagulant therapy for purposes other than apheresis treatment
  • Any hypercoagulable disorder
  • Known infection with Hepatitis B or C, or HIV
  • Severe anemia
  • Leukopenia or granulocytopenia
  • Evidence of current systemic infection
  • Malignancy
  • Pregnant, lactating or planning to become pregnant during the course of the investigational study
  • Used within the last 30 days, an investigational drug, biologic or device or 5 half-lives, if known, for any investigational drug or biologic

Key Trial Info

Start Date :

July 1 2004

Trial Type :

INTERVENTIONAL

End Date :

July 1 2006

Estimated Enrollment :

168 Patients enrolled

Trial Details

Trial ID

NCT00102193

Start Date

July 1 2004

End Date

July 1 2006

Last Update

September 8 2008

Active Locations (37)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 10 (37 locations)

1

Mayo Clinic Scottsdale

Phoenix, Arizona, United States, 85054

2

Providence Clinical Research

Burbank, California, United States, 91505

3

University of California, San Francisco

San Francisco, California, United States, 94143-1623

4

Rocky Mountain Gastroenterology Associates, PC

Wheat Ridge, Colorado, United States, 80033